Can a chemo combo without anthracyclines still beat breast cancer?
NCT ID NCT07687446
First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time
Summary
This study looks at how well a chemotherapy and immunotherapy combination works for early triple-negative breast cancer when the usual anthracycline drugs are left out. The researchers are focusing on patients who cannot take anthracyclines due to previous treatment, older age, or heart problems. They will measure how many patients have no cancer cells left at surgery, along with side effects and long-term outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If effective, this approach could offer a treatment option for patients with early triple-negative breast cancer who cannot tolerate standard anthracycline-based therapy.
- What could go wrong
- This is an observational study, not a controlled trial, so results may not prove cause and effect. The sample size is small, and findings may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER (TRIPLE NEGATIVE BREAST CANCER (TNBC)) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.